Dalteparin is NOT a recommended anticoagulant for chronic stroke prevention in atrial fibrillation
Dalteparin should only be used in atrial fibrillation patients as short-term bridging therapy during interruption of oral anticoagulants for procedures, not as primary long-term anticoagulation. The 2014 AHA/ACC/HRS guidelines explicitly state that for patients with non-valvular AF requiring stroke prevention, oral anticoagulants are recommended—specifically warfarin (INR 2.0-3.0), dabigatran, rivaroxaban, or apixaban 1. Low-molecular-weight heparins like dalteparin are reserved exclusively for bridging therapy when oral anticoagulation must be temporarily interrupted 1.
When Dalteparin May Be Used in AF Patients
Bridging therapy only:
- For patients with AF and mechanical heart valves undergoing procedures requiring warfarin interruption (Class I recommendation) 1
- For patients with AF without mechanical valves, bridging decisions should balance stroke versus bleeding risk (Class I recommendation) 1
- The guidelines do not specify exact dalteparin doses for AF bridging, but standard therapeutic LMWH dosing would apply
Standard Dalteparin Dosing (From FDA Label)
For therapeutic anticoagulation in other indications 2:
- Treatment dose VTE: 200 IU/kg subcutaneously once daily (maximum 18,000 IU), or 100 IU/kg twice daily
- Extended treatment: May reduce to 150 IU/kg daily after initial period
- Renal impairment (CrCl <30 mL/min): Monitor anti-Xa levels targeting 0.5-1.5 IU/mL 3
Critical Clinical Pitfalls
Do not use dalteparin as chronic AF anticoagulation. One small observational study 4 examined dalteparin (2 × 100 anti-Xa units/kg subcutaneously, maximum 2 × 10,000 units) for TEE-guided cardioversion with median 11-day duration, but this was short-term periprocedural use, not chronic therapy. This does not constitute evidence for long-term stroke prevention.
The 2024 ACC/AHA/ACCP/HRS guidelines 5 and 2024 ESC guidelines 6 continue to recommend DOACs as preferred agents over warfarin for non-valvular AF, with no role for chronic LMWH therapy. DOACs (apixaban, dabigatran, edoxaban, rivaroxaban) are preferred because they reduce intracranial hemorrhage risk and don't require INR monitoring 5.
Appropriate Long-Term Anticoagulation Strategy
For stroke prevention in non-valvular AF with CHA₂DS₂-VASc ≥2:
- First choice: DOAC at appropriate dose 5, 6
- Alternative: Warfarin (INR 2.0-3.0, time in therapeutic range >70%) 1
- Never: Chronic dalteparin or other LMWH
Special consideration for severe renal impairment (CrCl <15 mL/min or dialysis): Warfarin is reasonable (Class IIa), while dabigatran and rivaroxaban are not recommended (Class III: No Benefit) 1. Even in this population, dalteparin is not the recommended alternative.